摘要
目的 :评价他克莫司 (FK506)用于肾移植患者免疫抑制治疗的效果与安全性。方法 :对肾移植术后应用FK506的932例患者的资料进行回顾性分析。结果 :肾移植术后即应用FK506的547例患者 ,急性排斥反应发生率低 ;由环孢素A (CsA)改用FK506的385例患者 ,大部分排斥反应缓解 ,肝功能改善。FK506的主要不良反应有血糖升高和神经系统毒性。结论 :FK506是一种强效免疫抑制剂 ,还可用于CsA不能逆转排斥反应的挽救治疗。
OBJECTIVE:To objectively evaluate the immunosuppressive effect and safety of tacrolimus(FK 506) in renal transplant recipients METHODS:932 recipients receiving FK 506,reported in literature,were retrospectively analyzed RESU_LTS:The incidence of acute rejection was low in 547 recipients who received FK 506 immediately after transplantation Most of the recipients who received CsA and FK 506 successively showed alleviation of rejection and improvement of liver function The ARDs of FK 506 were rise of blood sugar(18 10%) and toxicity to nervous system(12 25%) CONCLUSION:FK 506 is a po_wer immunosuppressant and can be used to treat CsA-resistant rejection
出处
《中国药房》
CAS
CSCD
2002年第4期225-226,共2页
China Pharmacy
关键词
应用
他克莫司
环孢素A
肾移植
免疫抑制剂
tacrolimus(FK 506)
cyclosporin A
kidney transplantation
immunosuppressive agent
